Mannkind, Game-Chancer in Sachen Diabetik? (Seite 331)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 03.04.24 20:06:55 von
neuester Beitrag 03.04.24 20:06:55 von
Beiträge: 6.825
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 1
Gesamt: 593.804
Gesamt: 593.804
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,1900
USD
+0,72 %
+0,0300 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 52,25 | +93,52 | |
| 1,9000 | +59,66 | |
| 0,6000 | +57,48 | |
| 2,2999 | +25,68 | |
| 1,9200 | +23,87 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8500 | -12,97 | |
| 2,2900 | -17,63 | |
| 2,6700 | -28,03 | |
| 5,2300 | -32,95 | |
| 9,6900 | -33,06 |
Beitrag zu dieser Diskussion schreiben
Feedback
Servus, das stimmt nicht, dass Maxim Dendreon noch kurz vor der Pleite mit 10 US Dollar bewertet hat, das war ein Jahr zuvor, wenn nicht sogar noch länger!
Dendreon ist mit Mannkind nicht vergleichbar, die Schulden waren zu hoch bei Dendreon, das ist hier nicht der Fall, das Geld wird zwar zum Jahresende knapp, jedoch ist Mannkind mit Afrezza und der Technosphere Technologie im Stande Kapital zu besorgen bzw. auszulizensieren!
Dendreon ist mit Mannkind nicht vergleichbar, die Schulden waren zu hoch bei Dendreon, das ist hier nicht der Fall, das Geld wird zwar zum Jahresende knapp, jedoch ist Mannkind mit Afrezza und der Technosphere Technologie im Stande Kapital zu besorgen bzw. auszulizensieren!
Sorry aber Jason Kolbert ist nun wirklich kein Analyst auf welchen man hören sollte...
https://www.tipranks.com/analysts/jason-kolbert
Der hatte DNDN wenige Monate vor C11 noch mit USD 10.00 bewertet...
https://www.tipranks.com/analysts/jason-kolbert
Der hatte DNDN wenige Monate vor C11 noch mit USD 10.00 bewertet...
Wow, upgrade auf 4 US Dollar:Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here. (Updated - August 11, 2017 7:28 AM EDT)
Maxim Group initiates coverage on MannKind (NASDAQ: MNKD) with a Buy rating and a price target of $4.00.
Analyst Jason Kolbert said Afrezza could shift the paradigm in diabetes management and with the inhalable insulin now in the hands of a very capable management team, the focus is on execution.
"In the U.S., a conservative 5% share of the insulin market is a $350M opportunity," Kolbert commented. "At the current ~$120M market capitalization there is significant upside, in our view."
For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.
Shares of MannKind closed at $1.16 yesterday.
Stimmt, aber lieber nochmals eine KE als bankrott, vielleicht gibt's ja Mal einen Lizenzpartner für die Technosphere Technologie!😀
sehe einen Chinesen mit tiefen Taschen die Fa aufkaufend
Trading Spotlight
Antwort auf Beitrag Nr.: 55.482.072 von Magnetfeldfredy am 08.08.17 18:19:44mal sehen, bis ende des Jahres muss auf jedenfall kohle kommen, wie und woher auch immer
5 Things You'll Really Want to Know from MannKind's Q2 Update
MannKind Q2 results show some good news -- but there's still a long way to go for this biotech.
Keith Speights
(TMFFishBiz)
Aug 8, 2017 at 7:21AM
A few days ago, I posed a question in an article: How bad will MannKind Corporation's (NASDAQ:MNKD) second-quarter results look? We now know the answer to that question. The company announced its second-quarter results after the market closed on Monday. And those results were basically what I expected -- better, but still pretty bad.
There was some good news in MannKind's latest update, along with some bad news as well. Here are five things that you'll really want to know from the company's second-quarter results and its conference call to discuss those results and the days ahead.
Computer keyboard with red "2nd quarter button"
Image source: Getty Images.
1. Afrezza sales are growing
Perhaps the best news of all from MannKind's update was that Afrezza sales are increasing. Net revenue from the drug was $1.5 million, up 29% from the first quarter. Gross revenue increased even more, up 60% year over year to $2.6 million.
MannKind also provided guidance for Afrezza sales for the first time. The company expects net sales of the drug between $6 million and $10 million in the second half of 2017, with gross sales between $9 million and $14 million. This outlook reflects expectations of a not-so-insignificant uptick in sales for Afrezza (at least, it's not insignificant on a percentage basis).
2. Losses are growing, too
Now for the ugly part of MannKind's second-quarter results. The company's bottom line worsened in the second quarter. MannKind reported a net loss of $35.3 million, or $0.35 per share, in the second quarter. By comparison, the company posted a net loss of $30.0 million, or $0.33 per share, in the prior-year period. In the first quarter of 2017, MannKind recorded a net loss of $16.3 million, or $0.17 per share.
There were two main factors behind the bigger loss. First, MannKind's selling, general, and administrative expense increased considerably. However, that was to be expected as the company beefed up its sales force. Second, currency fluctuations delivered a major whammy, adding more than $6.8 million to total expenses.
3. Parting ways with TASE
Back in 2015, MannKind listed on the Tel Aviv Stock Exchange (TASE). The move was a nifty trick at the time that generated an additional $36.2 million in cash net of associated fees. MannKind CEO Michael Castagna announced on Monday, though, that the company was withdrawing from TASE.
While the decision a couple of years made sense, MannKind's delisting from TASE now should also be a positive step. According to Castagna, this will free up around 10 million preferred shares. MannKind will remain listed on the NASDAQ stock exchange.
4. A big milestone coming up
Castagna ranks the anticipated label change for Afrezza as one of the top keys to success for MannKind. The company has presented data to the FDA that it believes shows a differentiated pharmacokinetic/pharmacodynamic profile for Afrezza. In particular, MannKind hopes to convince the federal agency that Afrezza starts working within five minutes, is faster-acting than the competition, and, in blunt terms, is simply better altogether than many other diabetes treatments.
It's hard to overstate how important this potential label change could be for MannKind. Right now, the company can't legally make some of the claims for Afrezza that its team strongly feels are true. MannKind expects a decision in the third quarter. If all goes well, the company will launch the newly labeled product in the fourth quarter.
5. Staying alive
Two numbers in MannKind's second-quarter update won't give investors a warm-and-fuzzy feeling. The company reported cash and cash equivalents totaling $43.4 million at the end of June. However, MannKind expects to burn through $18 million to $24 million each quarter in the second half of this year. It doesn't take sophisticated math to calculate that the company will soon run out of money without something happening.
Castagna said that no one at MannKind is "losing sleep" over this situation, though. He noted that MannKind has several options for generating more capital, including issuing more shares and taking on additional debt.
Looking ahead
MannKind stock dropped around 13% in after-hours trading before climbing back to a loss of under 8%. It's understandable that investors weren't happy with the company's deeper loss in the second quarter and the fact that its cash is rapidly running out.
On the other hand, there are a few hopeful signs for MannKind. If the company gets its wishes fulfilled by the FDA on the label change, the larger sales force MannKind now has in place could be able to sell Afrezza more effectively than ever before. The company also has some intriguing potential for the use of its technology platform in delivering trepostinil for treatment of pulmonary arterial hypertension. And there's also the possibility that the company will find partners for its non-insulin Technosphere-based pipeline candidates.
All of those are if's and maybe's, though. As of now, we only have MannKind's current status -- improved, but still a long way to go.
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
MannKind Q2 results show some good news -- but there's still a long way to go for this biotech.
Keith Speights
(TMFFishBiz)
Aug 8, 2017 at 7:21AM
A few days ago, I posed a question in an article: How bad will MannKind Corporation's (NASDAQ:MNKD) second-quarter results look? We now know the answer to that question. The company announced its second-quarter results after the market closed on Monday. And those results were basically what I expected -- better, but still pretty bad.
There was some good news in MannKind's latest update, along with some bad news as well. Here are five things that you'll really want to know from the company's second-quarter results and its conference call to discuss those results and the days ahead.
Computer keyboard with red "2nd quarter button"
Image source: Getty Images.
1. Afrezza sales are growing
Perhaps the best news of all from MannKind's update was that Afrezza sales are increasing. Net revenue from the drug was $1.5 million, up 29% from the first quarter. Gross revenue increased even more, up 60% year over year to $2.6 million.
MannKind also provided guidance for Afrezza sales for the first time. The company expects net sales of the drug between $6 million and $10 million in the second half of 2017, with gross sales between $9 million and $14 million. This outlook reflects expectations of a not-so-insignificant uptick in sales for Afrezza (at least, it's not insignificant on a percentage basis).
2. Losses are growing, too
Now for the ugly part of MannKind's second-quarter results. The company's bottom line worsened in the second quarter. MannKind reported a net loss of $35.3 million, or $0.35 per share, in the second quarter. By comparison, the company posted a net loss of $30.0 million, or $0.33 per share, in the prior-year period. In the first quarter of 2017, MannKind recorded a net loss of $16.3 million, or $0.17 per share.
There were two main factors behind the bigger loss. First, MannKind's selling, general, and administrative expense increased considerably. However, that was to be expected as the company beefed up its sales force. Second, currency fluctuations delivered a major whammy, adding more than $6.8 million to total expenses.
3. Parting ways with TASE
Back in 2015, MannKind listed on the Tel Aviv Stock Exchange (TASE). The move was a nifty trick at the time that generated an additional $36.2 million in cash net of associated fees. MannKind CEO Michael Castagna announced on Monday, though, that the company was withdrawing from TASE.
While the decision a couple of years made sense, MannKind's delisting from TASE now should also be a positive step. According to Castagna, this will free up around 10 million preferred shares. MannKind will remain listed on the NASDAQ stock exchange.
4. A big milestone coming up
Castagna ranks the anticipated label change for Afrezza as one of the top keys to success for MannKind. The company has presented data to the FDA that it believes shows a differentiated pharmacokinetic/pharmacodynamic profile for Afrezza. In particular, MannKind hopes to convince the federal agency that Afrezza starts working within five minutes, is faster-acting than the competition, and, in blunt terms, is simply better altogether than many other diabetes treatments.
It's hard to overstate how important this potential label change could be for MannKind. Right now, the company can't legally make some of the claims for Afrezza that its team strongly feels are true. MannKind expects a decision in the third quarter. If all goes well, the company will launch the newly labeled product in the fourth quarter.
5. Staying alive
Two numbers in MannKind's second-quarter update won't give investors a warm-and-fuzzy feeling. The company reported cash and cash equivalents totaling $43.4 million at the end of June. However, MannKind expects to burn through $18 million to $24 million each quarter in the second half of this year. It doesn't take sophisticated math to calculate that the company will soon run out of money without something happening.
Castagna said that no one at MannKind is "losing sleep" over this situation, though. He noted that MannKind has several options for generating more capital, including issuing more shares and taking on additional debt.
Looking ahead
MannKind stock dropped around 13% in after-hours trading before climbing back to a loss of under 8%. It's understandable that investors weren't happy with the company's deeper loss in the second quarter and the fact that its cash is rapidly running out.
On the other hand, there are a few hopeful signs for MannKind. If the company gets its wishes fulfilled by the FDA on the label change, the larger sales force MannKind now has in place could be able to sell Afrezza more effectively than ever before. The company also has some intriguing potential for the use of its technology platform in delivering trepostinil for treatment of pulmonary arterial hypertension. And there's also the possibility that the company will find partners for its non-insulin Technosphere-based pipeline candidates.
All of those are if's and maybe's, though. As of now, we only have MannKind's current status -- improved, but still a long way to go.
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
So jetzt nochmal rein vor den Quartalszahlen heute. Es bleibt dabei: Afrezza wird das "Management" dieser Volkskrankheit revolutionieren oder ihnen geht vorher die Kohle aus...für heute rechne ich aber mit einen kleinen Umsatzsprung nachdem sie ihr ersten Fernsehspot platziert haben und einer noch ausreichenden Cash-Reserve. Guter Zeitpunkt mal mit zu zocken...
MannKind and One Drop Partner to Launch the A-ONE Clinical Trialthe One Drop digital diabetes care platform
VALENCIA, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and One Drop today announced the first step of their collaboration with the launch of the A-ONE study, a randomized controlled trial investigating the use of Afrezza® inhaled insulin and One Drop's integrated digital diabetes care platform.
In May 2017, MannKind and One Drop announced a memorandum of understanding to explore collaborations related to One Drop | Premium (i.e., One Drop | Mobile app, One Drop | Chrome meter and test strips, One Drop | Experts coaching service) and Afrezza®, MannKind's inhaled rapid-acting mealtime insulin. One goal of the collaboration is to identify ways of simplifying the complexity of starting and staying on mealtime insulin along with Customized Coaching to help people achieve their A1C goals.
Appropriate people with type 2 diabetes who meet inclusion criteria will be randomized to one of two treatment arms: Afrezza® with One Drop | Premium — or — One Drop | Premium alone. Changes in hemoglobin A1C, quality of life, self-care, treatment satisfaction, and other metrics will be assessed. People with type 2 diabetes interested in learning more should email Aone@onedrop.today.
Dr. Raymond Urbanski, Chief Medical Officer of MannKind Corporation, said, "This study is intended to evaluate whether combining a solutions-oriented digital disease management platform like One Drop with an innovative drug like Afrezza® will provide patients with an improved ability to manage their diabetes."
"One Drop is a unique, fully integrated solution with the prospects of a huge health benefit," says Dr. Chandra Osborn, VP of Health and Behavioral Informatics at One Drop. "We know each piece of the puzzle works, and now we want to see how well they work together. With 9 peer-reviewed outcomes shared at medical meetings and a paper in press at JMIR Diabetes, One Drop is committed to delivering the most effective diabetes management solution in the market. The combination of One Drop with inhaled insulin could offer consumers, health care providers, and payers a potentially powerful solution with unprecedented benefits."
"Diabetes technology is evolving in a very exciting way," said Jeff Dachis, CEO and Founder of One Drop. "But not surprisingly for the vast majority of people with diabetes worldwide, expensive sensors, automated insulin delivery solutions, or call center approaches to care can create barriers and challenges to effective disease management. However, we are excited to evaluate whether a completely integrated digital diabetes therapeutics platform — encompassing evidence-based interventions, ADA-recognized diabetes education and coaching, wireless blood glucose tracking, user-centered design, robust data science, and an innovative pharmaceutical product like MannKind's Afrezza — can deliver improved health outcomes at a fraction of the cost of current standards of care."
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website. For more information about Afrezza, please visit www.afrezza.com.
ABOUT ONE DROP
One Drop (Informed Data Systems Inc.) is a digital health company harnessing the power of mobile computing and data science to transform the lives of everyone with diabetes worldwide.
The One Drop platform is evidence-based and clinically effective. It brings affordable, accessible diabetes care to everyone with diabetes and a smartphone, as well as their insurers and health care providers. One Drop's current offerings include:
· One Drop | Chrome: One Drop's FDA-approved, CE-certified Bluetooth wireless blood glucose monitoring system, which meets the highest standards of clinical accuracy and wirelessly transmits blood glucose data to the cloud via the One Drop | Mobile app for iOS and Android.
· One Drop | Plus: One Drop's newest subscription offerings, providing 50 to 100 blood glucose test strips per month for One Drop | Chrome and unlimited coaching via One Drop | Experts, starting at $13 per month.
· One Drop | Premium: One Drop's unlimited subscription, providing unlimited blood glucose test strips for One Drop | Chrome and unlimited coaching via One Drop | Experts, starting at $33 per month.
· One Drop | Experts: One Drop's 24/7, on-demand, digital diabetes education and coaching service, available as a standalone subscription, starting at $11 per month.* Each One Drop | Experts subscriber has his/her own "Expert" (Certified Diabetes Educator) available 24/7 for guidance, support, and anytime care. Experts deliver personalized digital therapeutics programs, including ADA-recognized diabetes education, to help people with diabetes define and achieve their health management goals. Subscribers can communicate with their Experts anytime via in-app chat; all data recorded in the app is available to Experts in real-time, allowing them to provide personalized behavioral guidance when subscribers need it most — no appointments necessary.
· One Drop | Mobile: One Drop's free, award-winning, cloud-based diabetes management solution delivered entirely via mobile app on iOS and Android. One Drop | Mobile provides real-time and historical blood glucose data and analytics to people with diabetes and their healthcare providers, allowing both to see relationships between specific health behaviors and health outcomes. One Drop | Mobile includes a fully-featured Apple WatchOS app for logging and analyzing diabetes data on the go. One Drop | Mobile is the only diabetes management platform that offers comprehensive self-care, peer-support, and expert support all in one place.
· One Drop | Professional: One Drop's HIPPA-compliant enterprise solution for insurers, healthcare provider networks, self-insured employers, and drug/device manufacturers seeking to dramatically improve health outcomes and lower the cost of caring for people with diabetes. One Drop | Professional delivers real-time data, real-time messaging, custom branding, custom content delivery, custom educational support, EMR/EHR integration, and the most affordable, effective, turnkey diabetes solution in market.
One Drop | Chrome is sold exclusively by One Drop (iOS, Android, and http://onedrop.today/), Amazon (http://www.amazon.com), and Apple (http://store.apple.com). One Drop's consumer subscription services are available for purchase in-app (iOS and Android) and at http://onedrop.today. The One Drop | Mobile solution is available for free download worldwide (iOS and Android). For more information, contact just@onedrop.today.
*The American Diabetes Association recognizes this education service as meeting the National Standards for Diabetes Self-Management Education and Support.
Quelle: Mannkind Corporation
MannKind and One Drop Partner to Launch the A-ONE Clinical Trialthe One Drop digital diabetes care platform
VALENCIA, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and One Drop today announced the first step of their collaboration with the launch of the A-ONE study, a randomized controlled trial investigating the use of Afrezza® inhaled insulin and One Drop's integrated digital diabetes care platform.
In May 2017, MannKind and One Drop announced a memorandum of understanding to explore collaborations related to One Drop | Premium (i.e., One Drop | Mobile app, One Drop | Chrome meter and test strips, One Drop | Experts coaching service) and Afrezza®, MannKind's inhaled rapid-acting mealtime insulin. One goal of the collaboration is to identify ways of simplifying the complexity of starting and staying on mealtime insulin along with Customized Coaching to help people achieve their A1C goals.
Appropriate people with type 2 diabetes who meet inclusion criteria will be randomized to one of two treatment arms: Afrezza® with One Drop | Premium — or — One Drop | Premium alone. Changes in hemoglobin A1C, quality of life, self-care, treatment satisfaction, and other metrics will be assessed. People with type 2 diabetes interested in learning more should email Aone@onedrop.today.
Dr. Raymond Urbanski, Chief Medical Officer of MannKind Corporation, said, "This study is intended to evaluate whether combining a solutions-oriented digital disease management platform like One Drop with an innovative drug like Afrezza® will provide patients with an improved ability to manage their diabetes."
"One Drop is a unique, fully integrated solution with the prospects of a huge health benefit," says Dr. Chandra Osborn, VP of Health and Behavioral Informatics at One Drop. "We know each piece of the puzzle works, and now we want to see how well they work together. With 9 peer-reviewed outcomes shared at medical meetings and a paper in press at JMIR Diabetes, One Drop is committed to delivering the most effective diabetes management solution in the market. The combination of One Drop with inhaled insulin could offer consumers, health care providers, and payers a potentially powerful solution with unprecedented benefits."
"Diabetes technology is evolving in a very exciting way," said Jeff Dachis, CEO and Founder of One Drop. "But not surprisingly for the vast majority of people with diabetes worldwide, expensive sensors, automated insulin delivery solutions, or call center approaches to care can create barriers and challenges to effective disease management. However, we are excited to evaluate whether a completely integrated digital diabetes therapeutics platform — encompassing evidence-based interventions, ADA-recognized diabetes education and coaching, wireless blood glucose tracking, user-centered design, robust data science, and an innovative pharmaceutical product like MannKind's Afrezza — can deliver improved health outcomes at a fraction of the cost of current standards of care."
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website. For more information about Afrezza, please visit www.afrezza.com.
ABOUT ONE DROP
One Drop (Informed Data Systems Inc.) is a digital health company harnessing the power of mobile computing and data science to transform the lives of everyone with diabetes worldwide.
The One Drop platform is evidence-based and clinically effective. It brings affordable, accessible diabetes care to everyone with diabetes and a smartphone, as well as their insurers and health care providers. One Drop's current offerings include:
· One Drop | Chrome: One Drop's FDA-approved, CE-certified Bluetooth wireless blood glucose monitoring system, which meets the highest standards of clinical accuracy and wirelessly transmits blood glucose data to the cloud via the One Drop | Mobile app for iOS and Android.
· One Drop | Plus: One Drop's newest subscription offerings, providing 50 to 100 blood glucose test strips per month for One Drop | Chrome and unlimited coaching via One Drop | Experts, starting at $13 per month.
· One Drop | Premium: One Drop's unlimited subscription, providing unlimited blood glucose test strips for One Drop | Chrome and unlimited coaching via One Drop | Experts, starting at $33 per month.
· One Drop | Experts: One Drop's 24/7, on-demand, digital diabetes education and coaching service, available as a standalone subscription, starting at $11 per month.* Each One Drop | Experts subscriber has his/her own "Expert" (Certified Diabetes Educator) available 24/7 for guidance, support, and anytime care. Experts deliver personalized digital therapeutics programs, including ADA-recognized diabetes education, to help people with diabetes define and achieve their health management goals. Subscribers can communicate with their Experts anytime via in-app chat; all data recorded in the app is available to Experts in real-time, allowing them to provide personalized behavioral guidance when subscribers need it most — no appointments necessary.
· One Drop | Mobile: One Drop's free, award-winning, cloud-based diabetes management solution delivered entirely via mobile app on iOS and Android. One Drop | Mobile provides real-time and historical blood glucose data and analytics to people with diabetes and their healthcare providers, allowing both to see relationships between specific health behaviors and health outcomes. One Drop | Mobile includes a fully-featured Apple WatchOS app for logging and analyzing diabetes data on the go. One Drop | Mobile is the only diabetes management platform that offers comprehensive self-care, peer-support, and expert support all in one place.
· One Drop | Professional: One Drop's HIPPA-compliant enterprise solution for insurers, healthcare provider networks, self-insured employers, and drug/device manufacturers seeking to dramatically improve health outcomes and lower the cost of caring for people with diabetes. One Drop | Professional delivers real-time data, real-time messaging, custom branding, custom content delivery, custom educational support, EMR/EHR integration, and the most affordable, effective, turnkey diabetes solution in market.
One Drop | Chrome is sold exclusively by One Drop (iOS, Android, and http://onedrop.today/), Amazon (http://www.amazon.com), and Apple (http://store.apple.com). One Drop's consumer subscription services are available for purchase in-app (iOS and Android) and at http://onedrop.today. The One Drop | Mobile solution is available for free download worldwide (iOS and Android). For more information, contact just@onedrop.today.
*The American Diabetes Association recognizes this education service as meeting the National Standards for Diabetes Self-Management Education and Support.
Quelle: Mannkind Corporation
[urlhttps://www.youtube.com/watch?v=OZPKIh57G0s&feature=youtu.be][/url]Dieser Mann spricht in den höchsten Tönen über seine Erfahrungen mit Afrezuza vor dem Congress, Afrezza ist noch lange nicht tot, im Gegenteil
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
